Testing effectiveness (Phase 2)Study completedNCT00711230What this trial is testingRepeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve PatientsWho this might be right forHIV Infection Genetic Immunity 36
Testing effectiveness (Phase 2)Study completedNCT01155037What this trial is testingSafety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected AdultsWho this might be right forHIV Infection Oswaldo Cruz Foundation 450
Not applicableStudy completedNCT00050063What this trial is testingEffects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV DrugsWho this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 78
Early research (Phase 1)Study completedNCT00000977What this trial is testingActive Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and ToxicityWho this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 52
Early research (Phase 1)Study completedNCT03391375What this trial is testingEvaluation of the Effect of Late Boost on HIV-uninfected Vaccines From EV06 TrialWho this might be right forHIV/AIDS EuroVacc Foundation 49
Early research (Phase 1)Study completedNCT00000632What this trial is testingA Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59Who this might be right forHIV InfectionsHIV Seronegativity National Institute of Allergy and Infectious Diseases (NIAID) 14
Early research (Phase 1)Looking for participantsNCT07530198What this trial is testingHIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong KongWho this might be right forHuman Immunodeficiency VirusHuman Immunodeficiency Virus I Infection Immuno Cure Holding (HK) Limited 22
Early research (Phase 1)Study completedNCT00001044What this trial is testingA Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.Who this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 80
Post-approval studies (Phase 4)Study completedNCT04982614What this trial is testingHPV Vaccination in HIV Infected and HIV Uninfected Adolescents in EswatiniWho this might be right forHPV InfectionHivHPV Vaccine Columbia University 1,403
Early research (Phase 1)Study completedNCT00384787What this trial is testingSafety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected AdultsWho this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 90
Testing effectiveness (Phase 2)Study completedNCT01412801What this trial is testingMagnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their OffspringsWho this might be right forStreptococcal InfectionsGram-Positive Bacterial InfectionsBacterial Infections Novartis Vaccines 270
Testing effectiveness (Phase 2)Study completedNCT00604175What this trial is testingSafety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected WomenWho this might be right forHIV InfectionsSexually Transmitted Diseases National Institute of Allergy and Infectious Diseases (NIAID) 319
Testing effectiveness (Phase 2)Active Not RecruitingNCT04983030What this trial is testingSafety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected AdultsWho this might be right forHIVAcquired Immunodeficiency SyndromeImmunologic Deficiency Syndrome, Acquired+2 more Boris Juelg, MD PhD 36
Early research (Phase 1)Study completedNCT00001026What this trial is testingA Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive IndividualsWho this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 56
Large-scale testing (Phase 3)Study completedNCT02817451What this trial is testingDTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected InfantsWho this might be right forDiphtheriaTetanusPertussis+3 more Sanofi Pasteur, a Sanofi Company 53
Large-scale testing (Phase 3)UnknownNCT01512784What this trial is testingLong Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young AdultsWho this might be right forHPVHIV University of Milan 100
Not applicableStudy completedNCT00150098What this trial is testingProject UNITY - HIV Risk Reduction and Vaccine Education InterventionsWho this might be right forHIV InfectionsHepatitis B New York Blood Center 400
Early research (Phase 1)Study completedNCT00000667What this trial is testingA Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ CellsWho this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 20
Early research (Phase 1)Study completedNCT00261001What this trial is testingSafety Study Comparing a Vaccine Transcutaneous Administration to the Intramuscular RouteWho this might be right forHealthy VolunteersHIV Infection Objectif Recherche Vaccins SIDA 38
Testing effectiveness (Phase 2)Ended earlyNCT01424501What this trial is testingSafety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB DiseaseWho this might be right forTuberculosis GlaxoSmithKline 142